.
MergerLinks Header Logo

New Deal


Announced

Novartis to acquire Chinook Therapeutics for $3.5bn.

Synopsis

Novartism, a healthcare company that provides solutions to address the evolving needs of patients worldwide, agreed to acquire Chinook Therapeutics, a biotechnology company that specializes in the fields of therapeutics and life science, for $3.5bn. "We are pleased that Novartis recognizes the significant value that the Chinook team has built with our pipeline of clinical and preclinical programs for patients with rare, severe chronic kidney diseases. We believe this transaction is great news for kidney disease patients and the programs we have built at Chinook. Through this merger, Novartis can apply its substantial resources to pursue broader development efforts and commercialization of atrasentan, zigakibart (BION-1301) and other programs in our pipeline to build its global renal therapeutic area,” Eric Dobmeier, Chinook Therapeutics CEO and President.

Show Details & Financials

Market Context

Sort

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US